Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
复制标题
DOI：
10.1136/annrheumdis-2020-217485
复制
发表时间：
2020-09-01
影响因子：
27.4
通讯作者：
de Jong, Pascal Hendrik Pieter
中科院分区：
文献类型：
--
作者：
van Mulligen, Elise;Weel, Angelique E.;de Jong, Pascal Hendrik Pieter
目的评价两种渐进式减量策略的2年临床疗效。第一种策略包括首先减少常规合成疾病缓解抗风湿药物（csDMARDs）（即甲氨蝶呤占90%左右），然后是肿瘤坏死因子抑制剂（tnf抑制剂），第二种策略包括首先减少tnf抑制剂，然后是csDMARD。方法本多中心单盲随机对照试验纳入疾病控制良好的类风湿性关节炎（RA）患者，连续3个月，以44个关节的疾病活动评分（DAS）来定义
Objectives To evaluate the 2-year clinical effectiveness of two gradual tapering strategies. The first strategy consisted of tapering the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) first (i.e., methotrexate in similar to 90%), followed by the tumour necrosis factor inhibitor (TNF-inhibitor), the second strategy consisted of tapering the TNF-inhibitor first, followed by the csDMARD.Methods This multicentre single-blinded randomised controlled trial included patients with rheumatoid arthritis (RA) with well-controlled disease for >= 3 consecutive months, defined as a Disease Activity Score (DAS) measured in 44 joints